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Abstract 
Motivation: The potential of the Bombali virus, a novel Ebolavirus, to cause disease in humans remains 
unknown. We have previously identified potential determinants of Ebolavirus pathogenicity in humans 
by analysing the amino acid positions that are differentially conserved (specificity determining positions; 
SDPs) between human pathogenic Ebolaviruses and the non-pathogenic Reston virus. Here, we in-
clude the many Ebolavirus genome sequences that have since become available into our analysis and 
investigate the amino acid sequence of the Bombali virus proteins at the SDPs that discriminate be-
tween human pathogenic and non-human pathogenic Ebolaviruses. 
Results: The use of 1408  Ebolavirus genomes (196 in the original analysis) resulted in a set of 166 
SDPs (reduced from 180), 146 (88%) of which were retained from the original analysis. This indicates 
the robustness of our approach and refines the set of SDPs that distinguish human pathogenic Ebo-
laviruses from Reston virus. At SDPs, Bombali virus shared the majority of amino acids with the human 
pathogenic Ebolaviruses (63.25%). However, for two SDPs in VP24 (M136L, R139S) that have been 
proposed to be critical for the lack of Reston virus human pathogenicity because they alter the VP24-
karyopherin interaction, the Bombali virus amino acids match those of Reston virus. Thus, Bombali 
virus may not be pathogenic in humans. Supporting this, no Bombali virus-associated disease out-
breaks have been reported, although Bombali virus was isolated from fruit bats cohabitating in close 
contact with humans, and anti-Ebolavirus antibodies that may indicate contact with Bombali virus have 
been detected in humans. 
Contact: m.n.wass@kent.ac.uk m.michaelis@kent.ac.uk 
Supplementary information: Supplementary data are available at Bioinformatics online. 
 
 
1 Introduction  
Ebolaviruses represent a serious public health concern. The past few years 
have seen multiple outbreaks in Africa, including an epidemic between 
2013-16, which resulted in more than 28,000 cases and 11,000 deaths 
(Michaelis et al., 2016; Coltart et al., 2017; Lo et al., 2017). Until recently, 
only five species of Ebolavirus had been identified. Four of these Ebo-
lavirus species, Ebola virus, Sudan virus, Bundibugyo virus, and Taï forest 
virus are known to be pathogenic to humans, while the fifth, Reston virus, 
is not (Miranda and Miranda 2011; Michaelis et al., 2016; Cantoni et al., 
2016; Baseler et al., 2017). In August 2018, a new species of Ebolavirus, 
Bombali ebolavirus, was identified in the Bombali region of Sierra Leone 
(Goldstein et al., 2018). Currently, it is not known if Bombali virus causes 
disease in humans.  
To investigate why Reston virus is not pathogenic in humans and the other 
four Ebolaviruses are, we have previously identified amino acid positions 
that are differentially conserved between these two groups (specificity de-
termining positions; SDPs; Rausell et al., 2010) and analysed their effects 
on protein structure and function together with the changes associated with 
Ebola virus adaptation to new species (Pappalardo et al., 2016; 2017). The 
results indicated that certain SDPs in the karyopherin-binding region of 
the Ebolavirus protein VP24 are critical determinants of species-specific 
Ebolavirus pathogenicity (Pappalardo et al., 2016; 2017). Here, we first 
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update our comparison of human pathogenic and non-human pathogenic 
Ebolaviruses by including the many Ebolavirus genome sequences that 
have become available in the last few years. Then we use this dataset to 
analyse the Bombali virus sequence at amino acid positions that are asso-
ciated with human pathogenicity. 
2 Results 
2.1 Identifying determinants of Ebolavirus pathogenicity 
Our original study was based on a set of 196 Ebolavirus genomes. We 
identified 180 SDPs that were differentially conserved between Reston vi-
rus and the human pathogenic Ebolaviruses, of which 47 mapped to pro-
tein structures and eight were proposed to have an effect on protein struc-
ture and function (Pappalardo et al., 2016; Michaelis et al., 2016). Here, 
we have expanded the dataset to 1,408 Ebolavirus genomes (those retained 
after filtering an initial set of 2,076 genomes for quality and completeness 
– see supplementary methods). This represents 7.5 times more sequences 
than used in the original study and also includes an increase in the number 
of Reston virus sequences from 17 to 27. 
Phylogenetic analysis of the whole genome sequence and for each of the 
seven Ebolavirus proteins clearly separated each of the Ebolavirus species 
(Supplementary Figure 1). However, the phylogenetic trees did not sepa-
rate Reston virus from the human pathogenic Ebolavirus species (Supple-
mentary Figure 1).  
High levels of conservation were observed within each species (Supple-
mentary Figure 2).  Comparison of Reston virus proteins to the proteins of 
the other four human pathogenic species showed that there is greater di-
vergence in GP, NP, VP30 and VP35, with conservation between 58%-
69%, whereas VP24, L and VP40 have a higher level of conservation (74-
81%; Supplementary Figure 2H).  
Table 1. Summary of the number of SDPs lost, retained and gained in 











NP 29 5 24 0 24 
VP35 19 0 19 3 22 
VP40 9 0 9 7 16 
GP 30 11 19 1 20 
VP30 17 1 16 4 20 
VP24 9 0 9 2 11 
L 67 17 50 3 53 
 
The increased number of Ebolavirus genomes resulted in a slight reduction 
of SDPs from 180 (originally reported as 189 but SDPs in sGP and GP 
were identical as they share a common N-terminus) to 166 in the seven 
Ebolavirus proteins (Figure1, Table 1 and Supplementary Tables 1-7). 
Overall, 146 SDPs were retained, 34 were lost and 20 new SDPs were 
identified. No SDPs were lost in VP24 or VP35, and only a single SDP 
was lost in VP30. New SDPs were identified for each of these proteins 
ranging from two for VP24 to seven for VP40 (Figure1, Table 1). More 
SDPs were lost in NP, GP and L, ranging from five for NP to 17 for L. At 
the same time, no SDPs were gained in NP, one was gained in GP and 
three in L (Figure 1, Table 1). 
Analysis of the SDPs at the codon level revealed that for the 27 Reston 
virus sequences, only 10 SDPs showed any variation in codon usage, and 
for those ten positions there were always two codons present that repre-
sented synonymous changes. For five of these SDPs, only a single se-
quence contained a different codon and for the other five the codon usage 
was more closely balanced (Supplementary Table 8). For the pathogenic 
species, most amino acids at SDPs were encoded by multiple codons, with 
only 12 SDPs where a single codon was present (supplementary tables 9-
15). 115 SDPs have only synonymous changes, while 39 SDPs also have 
non-synonymous changes (35 of these 39 also have synonymous changes; 
supplementary tables 9-15). The synonymous changes largely (106 of 
115) represent differences in the codon usage between the different path-
ogenic species (Supplementary Tables 9-15). 23 of the non-synonymous 
changes are due to different codon usage between the species, while the 
remaining 16 non-synonymous changes occur in Ebola viruses. This 
shows that while  variation occurs at the codon level, the amino acids en-
coded at  SDPs are highly conserved. 
2.2 Structural Analysis of SDPs 
It was possible to map 92 of the 166 SDPs onto protein structures or mod-
els (supplementary methods; Table 2; Supplementary Tables 17-18), com-
pared to 47 SDPs in the previous study (Pappalardo et al., 2016). This was 
partly due to greater structural coverage of the proteins, with a structure 
of the N terminal region of VP35 (Chanthamontri et al., 2018; Zinzula et 
al., 2019) now available and also a template to model the structure of L 
(Supplementary Figure 3).  Overall, the amino acid changes at SDPs rep-
resent conservative changes, with the majority of BLOSUM62 substitu-
tion score values being one or greater (Figure 2A). Most are predicted to 
be slightly destabilising to the protein structure (Figure 2B), although this 
analysis only considered individual SDPs in isolation. One quarter of the 
SDPs (42) are located in the interior of the protein with the remaining three 
quarters having more than 20% relative solvent accessibility (Figure2C). 
These observations are consistent with the majority of SDPs having minor 
effects on protein structure and function. 
Our previous structural analysis proposed a set of eight SDPs that were 
highly likely to alter protein structure and function, and a further five for 
which there was lower confidence (Pappalardo et al., 2016). Twelve of 
these 13 SDPs were retained in the current analysis, with only the lower 
confidence NP A705R no longer being sufficiently conserved to be iden-
tified as an SDP.  
Table 2. Summary of SDPs per ebolavirus protein, and the predicted 
functional impacts. SDPs were assessed to have an effect on the protein 
stability/integrity or protein-protein interactions. These were classed as 
“probable” or “possible” depending on the strength of evidence supporting 
the effect. of the number of SDPs lost, retained and gained in the updated 
set of SDPs.  










NP 24 8 0 0 1 0 
VP35 22 15 0 1 0 0 
VP40 16 13 1 1 0 0 
GP 20 10 0 0 0 3 
VP30 20 5 0 1 0 0 
VP24 11 10 1 4 0 0 
L 53 31 0 0 0 0 
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Fig1: Specificity Determining Positions (SDPs) identified between human-pathogenic Ebolaviruses and Reston virus. The coloured bars represent the lengths of the protein sequence 
alignments, and each bar is labelled with the name of the protein that it represents. The solid black line represents the Jensen-Shannon conservation score. Dotted red lines represent SDPs. 
Previously identified SDPs that were lost in the updated analysis are coloured red, dashed grey lines (dot-dash) represent SDPs that were retained, and dashed blue lines represent new SDPs 
that have been identified. Note – x-axes differ in their scales between subplots 
 
Of the 20 newly identified SDPs, 10 were mapped onto protein struc-
tures (Table 2). Among these SDPs, we identified only one (VP24 
R140S) that was likely to have an effect on protein structure and func-
tion. This results in nine SDPs overall with high confidence of having 
an effect on protein structure and function and four with lower confi-
dence (Supplementary Table 19). 
The VP24 SDP R140S is located in the VP24 interface site with human 
karyopherin α5 (KPNA5;  Xu et al., 2014) where four other SDPs are 
located (T131S, N132T, M136L, and Q139R). R140 can form hydro-
gen bonds with residues E476 (backbone) and Y477 (sidechain) in 
KPNA5, and also with the sidechain of E113 in VP24 (Figure 3A,B). 
Reston virus S140 would still have the potential to form hydrogen 
bonds but not as extensively as R140. We have previously proposed  
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Fig 2: Characteristics of the 
Specificity Determining Posi-
tions (SDPs) between human 
pathogen Ebolaviruses and 
Reston virus. A) BLOSUM62 
scores for the whole set of 
SDPs. B) mCSM predicted sta-
bility changes for the whole set 
of SDPs. B) Relative Solvent 
Accessibility for the whole set 




that T131S, M136L and Q139R were likely to alter the binding of Reston 
virus VP24 to karyopherins, which may affect the ability of VP24 to in-
hibit the host interferon response (Pappalardo et al., 2016). The addition 
of R140S further supports this hypothesis, suggesting that this VP24 in-
terface is vital to determining species-specific pathogenicity. Our hypoth-
esis has recently been supported by experimental studies. Guito et al., 
(2016) showed that Reston virus VP24 is less effective at inhibiting the 
human interferon response. Further, histidine is present at residue 140 in 
Bundibugyo virus VP24 and has been implicated in reduced efficiency of 
downregulating interferon signalling (Schwarz et al. 2017). 
2.3 Comparison of Bombali virus with the other Ebo-
laviruses  
Phylogenetic analysis of the genome sequences and of six of the seven 
Ebolavirus proteins grouped Bombali virus with Ebola, Sudan, Tai forest 
and Bundibugyo viruses, with Sudan and Reston viruses on a separate 
branch (Supplementary Figure 1). For the seventh Ebolavirus protein, 
VP30, Bombali virus was grouped with Reston virus and the four known 
human-pathogenic species were on a separate branch (Supplementary fig-
ure 1k,l). While the phylogenetic analysis tends to group Bombali virus 
with human pathogenic Ebolavirus species, the pathogenic and non-path-
ogenic species are not clearly separated, making it difficult to infer from 
this phylogenetics analysis if Bombali virus is likely to be pathogenic in 
humans. 
When considering the SDPs that differentiate human pathogenic and non-
pathogenic Ebolaviruses, in Bombali virus the majority of amino acids at 
these positions (105; 63.25%) were identical to the human pathogenic 
Ebolaviruses, while 21 (12.65%) were shared between Bombali virus and 
Reston virus, and 40 (24.10%) were unique to Bombali virus (Supplemen-
tary Table 20). For the two available Bombali virus sequences, the amino 
acids present at SDPs agreed for all but one of the positions (VP24 
R140S), where one of the sequences had the amino acid present in the 
human pathogenic viruses (R), while the other sequence contained the 
amino acid present in Reston virus (S).  
With Bombali virus reported to have a 55–59% similarity to the other Ebo-
lavirus species (Goldstein et al., 2018), the Ebola-Bombali SDP residue 
similarity is about 15% higher than the overall average, indicating high 
conservation amongst these positions, consistent with previous findings 
(Pappalardo et al., 2016). For all of the individual proteins, the Bombali 
sequences have greater agreement with the amino acids present in human 
pathogenic species at SDPs (30.0% (VP30) to 77.36% (L)), while the 
agreement with Reston virus is only 10%-19% (Supplementary Table 20).  
Table 3. comparison of Bombali virus sequences with the nine SDPs 
identified as having a likely functional impact on human pathogenicity.  
Protein SDP Bombali 
agreement 
VP24 T131S EBOV 
VP24 M136L RESTV 
VP24 Q139R RESTV 
VP24 R140S EBOV/RESTV 
VP24 T226A EBOV 
VP30 R262A EBOV 
VP35 E269D EBOV 
VP40 P85T EBOV 
VP40 Q245P RESTV 
 
This suggests that Bombali virus is more closely aligned with the human 
pathogenic Ebolaviruses than with Reston virus. However, this may re-
flect closer relatedness among the African Ebolaviruses (Ebola virus, Su-
dan virus, Bundibugyo virus, Taï Forest virus, Bombali virus) compared 
to the Asian Reston virus, than similarities in human pathogenicity. In the 
phylogenetic analysis Bombali virus does group with most of the human 
pathogenic species (Supplementary Figure 1).  
Of the nine SDPs where we are confident that they are likely to alter pro-
tein structure and function (see above), Bombali virus has the same amino 
acid as the human pathogenic species at five positions and the same as 
Reston virus for three. The ninth position differs among the two available 
Bombali virus sequences (VP24 R140S; Table 3). While the majority of 
amino acids in Bombali virus at SDPs in VP24 agree with human patho-
genic Ebolavirus amino acids (73%; Supplementary Table 20), two critical 
SDPs in the VP24-karyopherin binding region (M136L, Q139R) are iden-
tical to Reston virus (Figure 3) (Pappalardo et al., 2016; 2017). Addition-
ally, at residue 132, an SDP which points away from the KPNA5 interface, 
there is a Bombali virus-specific amino acid (A132; N in EBOV, T in 
RESTV; Figure 3). This may indicate that the Bombali virus is not be as 
pathogenic as the human pathogenic Ebolaviruses in humans. 
3 Discussion 
In this study, we have updated our previous analysis of amino acid posi-
tions that are differentially conserved (SDPs) between human pathogenic  




















Fig 3. Specificity Determining Positions in VP24 suggest that Bombali virus may not be pathogenic in humans. A) SDPs in the VP24-Karyopherin-α5 interface. VP24 is shown in 
surface representation (grey) and karyopherin-α5 is shown as a mesh representation (teal). SDPs in VP24 are shown in red, and all residues within 5Å of karyopherin-α5 are shown in yellow. 
B) Hydrogen bonding of the SDP residue R140 in the Ebola virus VP24. VP25 (grey) and karyopherin-α5 (teal) are shown in cartoon format. Hydrogen bonds are represented by blue dashed 
lines. C) Agreement of Bombali virus sequences with the SDPs in the VP24-Karyopherin-α5 interface. VP24 (grey) is shown in cartoon representation, and Karyopherin-α5 (teal) is shown 
in surface representation. SDPs are shown in stick format, and coloured red where Bombali and Ebola virus agree, blue where Bombali virus agrees with Reston virus, orange where the 
Bombali virus amino acid is unique, and magenta where the amino acid present in the two Bombali virus sequences differ and one agrees with Ebola virus and the other with Reston virus.   
 
Ebolaviruses and the non-human pathogenic Reston virus by the inclusion 
of more than 1,200 additional genome sequences. We have also analysed 
the amino acids present in Bombali virus at the SDPs to infer whether 
Bombali virus may cause disease in humans. 
Our updated analysis of the SDPs that distinguish Reston virus from the 
four known human pathogenic Ebolavirus species, reduced the number of 
SDPs from 180 to 166. The vast majority of SDPs were retained from the 
original analysis, including all the SDPs that we have proposed are likely 
to affect protein structure and function and may have a role in determining 
pathogenicity. This demonstrates that our initial study using only 196 ge-
nomes provided robust results. While we have identified a small subset of 
SDPs that we propose may be associated with pathogenicity, this reflects 
those SDPs that we have been able to map to protein structure and use 
analysis of structures to identify a likely functional effect. It is of course 
possible that some of the SDPs that we have not been able to propose a 
functional effect for may have a role in determining pathogenicity. How-
ever, our updated results also further strengthen our findings that VP24 is 
central to determining host-specific pathogenicity (Pappalardo et al., 
2016; 2017), a notion that is further supported by experimental evidence 
showing that Reston virus VP24 is less effective than the other Ebolavirus 
VP24 proteins at inhibiting the host immune response (Guito et al., 2016). 
Since the number of available Reston virus sequences remains small, par-
ticularly compared to the number of sequences across the four human 
pathogenic species, a larger number of Reston virus sequences would  
likely further refine the set of SDPs by capturing the variation within 
Reston viruses.  
Our analysis of the Bombali virus sequence at the SDPs identified overall 
greater agreement with the human pathogenic Ebolaviruses. This could be 
the consequence of the common African origin of the human pathogenic 
Ebolaviruses and the Bombali virus, in contrast to the Asian Reston virus. 
The amino acids at SDPs in VP24 that we propose are most important in 
determining human pathogenicity are the same in Bombali virus and 
Reston virus. This suggests that Bombali virus may not be pathogenic, or 
have reduced pathogenicity, in humans. This is supported by the fact that 
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Bombali virus was isolated from fruit bats, which were cohabitating in 
houses and other populated areas (Goldstein et al., 2018) and although this 
makes human contact highly likely, no disease outbreaks have been re-
ported. Further, a study in the Bombali region detected anti-Ebola virus 
NP antibodies in humans without reports of disease (Mafopa et al., 2017). 
Although originally interpreted as evidence for asymptomatic Ebola virus 
infection, it is possible that this test actually detected antibodies against 
the then unknown Bombali virus that cross-reacted with Ebola virus anti-
gen. Hence, antibodies directed against Ebolavirus proteins may indicate 
exposure of humans to low- or non-human pathogenic Bombali virus in 
the Bombali region. 
In conclusion, based on our findings Bombali virus may be non-patho-
genic or of low pathogenicity in humans. However, since few mutations 
seem to be sufficient for Ebolavirus adaptation to a new species (Pappa-
lardo et al., 2017), human pathogenic Bombali viruses may emerge, in 
particular as the Bombali virus shares many more conserved amino acid 
positions with human pathogenic Ebolaviruses than the non-human path-
ogenic Reston virus and further human contact with Bombali virus is 
likely to occur. 
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